Hop­ing to brake a slow crash, Aduro's Stephen Isaacs hits the re­set but­ton, ax­ing staff in re­or­ga­ni­za­tion

With in­vestor con­fi­dence steadi­ly bleed­ing out over the last year, Aduro $ADRO CEO Stephen Isaacs has hit the re­set but­ton in an at­tempt to get back on track. 

The biotech said this morn­ing that it is whack­ing 37% of the staff and cir­cling its wag­ons around lead pro­grams part­nered with 2 promi­nent big phar­mas — No­var­tis and Eli Lil­ly — fo­cused on STING. The biotech is al­so pur­su­ing an in-house an­ti-APRIL an­ti­body, in de­vel­op­ment in on­col­o­gy and IgA nephropa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER